Antitumor effect potentiator

An anti-tumor and enhancer technology, applied in anti-tumor drugs, antibodies, medical preparations containing active ingredients, etc., can solve the problems of cancer patients who have not seen sufficient treatment effects, and achieve the effect of inhibiting development and inhibiting recurrence

Pending Publication Date: 2021-05-14
NAT CEREBRAL & CARDIOVASCULAR CENT +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there are cancer patients who do not see a sufficient therapeutic effect even through the activation of the immune system using immune checkpoint inhibitors, etc., and the development of further therapeutic methods is required

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor effect potentiator
  • Antitumor effect potentiator
  • Antitumor effect potentiator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1 The anti-tumor effect brought about by synbiotics / immune checkpoint inhibitor combined use in vivo

[0086] The mouse colon cancer cell line MC38 cells were transplanted into 7-week-old male C57BL / 6NCrSlc mice to make cell line transplantation model mice. Divided into control (Vehicle) group, synbiotics administration group, anti-PD-1 antibody administration group, synbiotics + anti-PD-1 antibody administration group {n=10 (Vehicle group), 5 (synbiotics administration group) , anti-PD-1 antibody administration group), 6 (synbiotics + anti-PD-1 antibody administration group)}.

[0087] Synbiotics were administered as follows: once a day after transplantation, 0.2 mL of synbiotics / mouse was administered orally every day for 28 days. The anti-PD-1 antibody was administered as follows: from the 7th day of tumor transplantation, 20 mg / kg anti-PD-1 antibody was administered intraperitoneally for the first time, and then administered every 6 days, and 10 mg / kg was a...

Embodiment 2

[0091] Example 2 In vivo effects on immune cells caused by combined use of synbiotics / immune checkpoints

[0092] The mouse colon cancer cell line MC38 cells were transplanted into 7-week-old male C57BL / 6NCrSlc mice to make cell line transplantation model mice. Divided into control (Vehicle) group, synbiotics administration group, anti-PD-1 antibody administration group, synbiotics + anti-PD-1 antibody administration group.

[0093] Synbiotics were administered as follows: once a day after transplantation, 0.2 mL of synbiotics / mouse was administered orally every day for 28 days. The anti-PD-1 antibody was administered as follows: from the 7th day of tumor transplantation, 20 mg / kg anti-PD-1 antibody was administered intraperitoneally for the first time, and then administered every 6 days, and 10 mg / kg was administered intraperitoneally for the second to fourth time. medication.

[0094] At the time of dissection, each tissue (spleen, tumor) was recovered, and the cells were ...

Embodiment 3

[0096] Example 3 In vivo effects of combined use of synbiotics / immune checkpoint inhibitors on control T cells (Treg) in the small intestine

[0097] The mouse colon cancer cell line MC38 cells were transplanted into 7-week-old male C57BL / 6NCrSlc mice to make cell line transplantation model mice. Divided into control (Vehicle) group, synbiotics administration group, anti-PD-1 antibody administration group, synbiotics + anti-PD-1 antibody administration group {n=10 (Vehicle group), 5 (synbiotics administration group) , anti-PD-1 antibody administration group), 6 (synbiotics + anti-PD-1 antibody administration group)}.

[0098] Synbiotics were administered as follows: once a day after transplantation, 0.2 mL of synbiotics / mouse was administered orally every day for 28 days. The anti-PD-1 antibody was administered as follows: from the 7th day of tumor transplantation, 20 mg / kg anti-PD-1 antibody was administered intraperitoneally for the first time, and then administered every 6...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is a novel means for activating an immune response in tumor immunotherapy in which an immune checkpoint inhibitor is used. An immune-checkpoint-inhibitor antitumor effect potentiator having probiotics and prebiotics as active ingredients.

Description

technical field [0001] The present invention relates to an anti-tumor effect enhancer and a tumor immune activator for activating tumor immune response and enhancing the resulting anti-tumor effect. Background technique [0002] Tumor immunotherapy is a therapy that acts on the immune surveillance mechanism that cancer patients themselves have, and strengthens the immunity against cancer, thereby inhibiting or treating the development of cancer. In recent years, in the progression of cancer, it has become clear that cancer cells themselves have a system to evade the immune surveillance mechanism, and as molecules used in such an evasion system, CTLA-4, PD-1, or PD- L1 and other immune checkpoint molecular groups. Furthermore, it has been reported that immune checkpoint inhibitors that block the function of these immune checkpoint molecular groups are extremely useful for enhancing immunity against cancer (Patent Document 1). [0003] In addition, Regulatory T cells (Treg),...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/747A23C15/00A23L2/00A23L2/02A23L2/38A23L2/52A23L33/135A61K31/702A61K35/745A61K39/395A61K45/06A61P35/00A61P37/04A61P43/00
CPCA61P43/00A61K31/702A61P35/00A61P37/04A61K35/745A61K39/395A61K35/747A23L33/135A61K45/06A61K2035/115A23V2002/00A23C9/123A23C15/123C07K16/2818C07K2317/76A61K2300/00A23V2200/3204A23V2200/324A23V2400/125A23V2400/519C07K16/2827
Inventor 寒川贤治野尻崇熊添基文田中爱健宍戸祐之朝原崇三浦崇仁谷口启介
Owner NAT CEREBRAL & CARDIOVASCULAR CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap